key: cord-0710744-hkyu0ib9
authors: Shahin, Khashayar; Zhang, Lili; Mehraban, Mohammad Hossein; Collard, Jean-Marc; Hedayatkhah, Abolghasem; Mansoorianfar, Mojtaba; Soleimani-Delfan, Abbas; Wang, Ran
title: Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2
date: 2022-02-10
journal: Microb Pathog
DOI: 10.1016/j.micpath.2022.105442
sha: c8f67bb89178dfdf195ecfdec7ee9c85b122a84e
doc_id: 710744
cord_uid: hkyu0ib9

In 2019, the world faced a serious health challenge, the rapid spreading of a life-threatening viral pneumonia, coronavirus disease 2019 (COVID-19) caused by a betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of January 2022 WHO statistics shows more than 5.6 million death and about 350 million infection by SARS-CoV-2. One of the life threatening aspects of COVID-19 is secondary infections and reduced efficacy of antibiotics against them. Since the beginning of COVID-19 many researches have been done on identification, treatment, and vaccine development. Bacterial viruses (bacteriophages) could offer novel approaches to detect, treat and control COVID-19. Phage therapy and in particular using phage cocktails can be used to control or eliminate the bacterial pathogen as an alternative or complementary therapeutic agent. At the same time, phage interaction with the host immune system can regulate the inflammatory response. In addition, phage display and engineered synthetic phages can be utilized to develop new vaccines and antibodies, stimulate the immune system, and elicit a rapid and well-appropriate defense response. The emergence of SARS-CoV-2 new variants like delta and omicron has proved the urgent need for precise, efficient and novel approaches for vaccine development and virus detection techniques in which bacteriophages may be one of the plausible solutions. Therefore, phages with similar morphology and/or genetic content to that of coronaviruses can be used for ecological and epidemiological modeling of SARS-CoV-2 behavior and future generations of coronavirus, and in general new viral pathogens. This article is a comprehensive review/perspective of potential applications of bacteriophages in the fight against the present pandemic and the post-COVID era.

The world witnessed a pneumonia outbreak of unknown etiology in Wuhan, China, in December 2019 (Huang et al., 2020) . The initial etiological studies disclosed that the disease causative agent was a virus of the Coronaviridae family named SARS-CoV-2. The substantial increase in detection of this virus in other parts of the world over a very short period of time led the World Health Organization (WHO) to declare a pandemic on March 1st, 2020. The clinical symptoms of this viral disease, which has become known as Coronavirus Disease 2019 , could range from mild respiratory disorders and fever to Acute Respiratory Distress Syndrome (ARDS), all potentially leading to death (Guan et al., 2020) . Based Many studies have been conducted on the supportive therapies, prevention, and management of this disease. Several promising vaccines, including BNT162B2 (Pfizer and BioNTech), mRNA-1273 (Moderna) and ChAdOx1 (AstraZeneca), have been introduced in the past two years (Guy et al., 2020) . The recommendations to prevent disease transmission or treat the patients are only based on the observed symptoms and the clinicians' point of view. When no antiviral or antiinflammatory medication is effective, supportive management and antibiotic therapy are the only remaining options as the main pillars of therapy protocols for coping with secondary bacterial infections .

Phylogenetically, coronaviruses are classified in the subfamily Orthocoronavirinae, of the family Coronaviridae, order Nidovirales (Banerjee et al., 2019) . Coronaviruses are divided into four genera: Alphacoronavirus (α-CoV) and Betacoronavirus (β-CoV), which primarily infect J o u r n a l P r e -p r o o f mammals as their hosts, and Gammacoronavirus (γ-CoV) and Deltacoronavirus (δ-CoV), which mainly infect birds (Woo et al., 2014; Schütze, 2016; Bossart and Duignan, 2018) . While coronaviruses are responsible for 20% of the common cold cases (Mesel-Lemoine et al., 2012) , they are the causative agents of some highly contagious and more severe respiratory infections over the last two decades. In addition to the current SARS-CoV-2 pandemic, two other viral pneumonia pandemics, namely severe acute respiratory syndrome and middle east respiratory syndrome, occurred in 2002 (first reported from China and rapidly spread throughout the world with the mortality rate of 11%) and in 2012 (first reported from Saudi Arabia and quickly spread to other countries with the mortality rate of 37%), respectively (Su et al., 2016) . In all three cases, the viruses most likely originated from bats and were transmitted to humans through animal hosts (Di Gennaro et al., 2020; Sabbah et al., 2020) . While β-CoV has not been reported in aquatic organisms yet, α-CoV and γ-CoV have been reported in aquatic mammals including Harbor Seals (α-CoV) (Bossart and Schwartz, 1990) , Pacific Harbor Seals (γ-CoV) (Nollens et al., 2010) and

Bottlenose Dolphins (γ-CoV) (Woo et al., 2014) . There is a slight genetic homology between α-CoV and γ-CoV with SARS-CoV-2 however both are involved in pneumonia in seals and cetaceans (Mordecai and Hewson, 2020) . Detection of the same coronaviruses in both coastal birds and aquatic mammals indicates potential transmission between hosts despite extreme differences in their habitats (Mordecai and Hewson, 2020) . Therefore, considering the high mutation rate (Martinez, 2020) , zoonotic (Su et al., 2016) , highly contagious (Di Gennaro et al., 2020) , and highly diverse, and omnipresence nature (Fuentes, 2020) , the emergence of new strains and species and consequently new types of pneumonia or recurring epidemics by no means cannot be ruled out. Undoubtedly, research on the behavior of SARS-CoV2 in the environment significantly deepen our understanding of the coronaviruses life cycle, distribution and infection behaviors.

Moreover, when dealing with highly-contiguous viruses with high mutations rate, it is very important to understand their stability at different stresses or through disinfection. On the other hand, such studies come with a very high risk and requires expensive state of the art equipment and facilities which in results extremely restricts the studies. Providing the minimum standard for studies on a highly contagious pathogen such as SARS-CoV-2 is strictly limited to facilities with the highest biosafety level. Considering the high risk of working with this virus, phage-based models with similar structures, genome, and ecological or epidemiological behavior would play a critical role in facilitating the research (Silverman and Boehm, 2020) .

The emergence of various types of resistance in bacteria, even to the newest and most potent antibiotics accompanied, the consequent side effects and complications of using standard or increased doses, necessitates finding alternative or complementary treatments (Kortright et al., 2019) . Phages (bacteriophages) are viruses that attack bacterial cells as their host, making them a potential antibacterial agent (Zhang et al., 2022; Bao et al., 2020; Bao et al., 2019; Housby and Mann, 2009; Shahin et al., 2021a) . Phage therapy will be successful if the number of pathogenic bacteria is reduced to an extent where the host defense system is competent enough to eliminate the remaining bacteria (Yazdi et al., 2020) . Many recent studies have shown the promising potential of phage therapy using only one bacteriophage or a phage cocktail or even in combination with either antibiotics or nanoparticles (Shahin et al., 2021b; Segall et al., 2019; Shahin et al., 2020a; Shahin et al., 2020b; Mansoorianfar et al., 2022; Shahin et al., 2022) . The scenario of panresistant secondary infections in SARS-CoV-2 portends a much more difficult time in post-COVID-19 era and even future pandemics. Hence, from both the public health and socio-economic points of views, there is an urgent need for reliable and accessible prevention, therapeutic or suppression strategies for SARS-CoV-2 epidemic.

J o u r n a l P r e -p r o o f

Phage display and its applications in molecular biology were introduced by Smith et al. in

Since then, the technique has increasingly attracted attention for two main reasons, expression and exposure of a diverse range of peptide ligands on the surface of phage, studying the interaction of the expresses ligands with target proteins or receptors (Huang et al., 2012a; Aghebati-Maleki et al., 2016) . The principle behind the technology is relatively simple; a desired corresponding DNA sequence is inserted in the nucleotide sequence of phages' coat proteins.

Expression of the coat proteins will simultaneously express the guest sequence and will be "displayed" on the surface of the phage (Huang et al., 2012a; Aghebati-Maleki et al., 2016) .

The proven potential of phage display can be used to treat novel strains of known pathogens or even newly emerged pathogens such as SARS-CoV-2 variants of concern, alpha, beta, delta and omicron (Sun and Ho, 2020) . Some of the main applications of phage display are evaluation of different antigen immunogenicity, epitope mapping, and vaccine and antibody development (Frenzel et al., 2016; Hess and Jewell, 2020) . These approaches and how to be used to fight against SARS-CoV-2 are discussed below and are depicted in Figure 1 .

Phage display has been used to determine the main epitope efficiency and specificity of different viruses (Figure 1 ). For example, as one of the major burdens on the health system, influenza virus undergoes antigenic shifts and drifts resulting in the emergence of new epitopes in a short period of time (Lim et al., 2008) . Khurana et al. (2009) and panned against the sera of convalescent individuals to discover the main antigenic epitopes of this virus to be used for vaccines development (Grifoni et al., 2021) . It is proved that envelope, nucleocapsid and spike proteins of SARS-CoV-2 have significant antigenic properties however, it is of great importance to discover the main epitopes in each of these proteins which can exert the strongest antigenic effect. In addition, SARS-CoV-2 undergoes

Through displaying various epitopes of SARS-CoV-2 proteins it is feasible to determine these antigenic epitopes and use them in developing new vaccines and serodiagnostic tools.

Furthermore, studying the interactions between SARS-CoV-2 epitopes and human antibodies will result in a comprehensive understanding of the virus infection mechanism and the capability and capacity of human antibodies to overcome the antigen invasion (Figure 1 ).

Another example of such application is epitope mapping of E32 and NS3 proteins of Hepatitis C virus through phage display. Pereboeva and Zhang et al. proved the antigenic properties of these proteins and candidate human CD81 as their specific receptor (Pereboeva et al., 2000; Zhang et al., 2007) . Many other viruses such as Hepatitis A, B, E, and HIV-1 have also been epitope mapped. Once the antigenic epitopes and the corresponding recognition sites of the antibodies are discovered, the collected data can particularly be used in vaccine development (Schofield et al., 2000; Larralde et al., 2007) . In this context, the immune serum of convalescent individuals serves as the target of biopanning; therefore, potential vaccine candidates against a specific disease are J o u r n a l P r e -p r o o f isolated. For instance, novel epitopes of HIV-1 and HBV have been discovered by constructing and screening peptide phage display libraries on convalescent serum from individuals. Potential epitopes have immunized animal models to produce virus-neutralizing antibodies (Folgori et al., 1994; Scala et al., 1999) . In another study, De Berardinis et al. identified epitopes of HIV-1 that can prime cytotoxic T-cell responses (De Berardinis et al., 2000) . This approach was employed for other coronaviruses as well. Van Den Brink et al. constructed an antibody phage library. They panned against the immobilized envelope (E) and nucleocapsid (N) proteins of SARS-CoV. A total of six MAbs with significant bind strength to these proteins were discovered. Epitope mapping revealed a substantial role for N479 residue in binding to MAbs (van den Brink et al., 2005) . Identification of a dominant epitope in the S2 domain of SARS-CoV spike protein was also carried out using the M13 phage display library (Zhong et al., 2005) . In a similar attempt to map the epitopes of SARS-CoV, Hua et al. identified TPEQQFT epitope that strongly binds to human

MAbs and could be used as a new scaffold in developing promising vaccines (Hua et al., 2006) .

Recent studies argued that N and E proteins of the SARS-CoV-2 have the most antigenic effect on the human body Udugama et al., 2020) . Therefore, phage display can be used for epitope mapping of SARS-CoV-2, and the sera of healed COVID-19 patients can be used to determine the main antigenic epitopes. Subsequently, the obtained data would be of extreme value in drug, vaccine or antibody development against SARS-CoV-2 (Figure 1 ) (Corral-Lugo et al., 2020; Fast and Chen, 2020) .

Another application of phage display has been in MAbs development (Aghebati-Maleki et al., 2016; Frenzel et al., 2016; Hess and Jewell, 2020) . Large libraries of natural or synthetic antibodies have been constructed using V gene repertoires of the immune system (Aghebati-Maleki et al., 2016) . In brief, these sequences are displayed on the surface of a phage. Then the interaction J o u r n a l P r e -p r o o f affinity and specificity of these MAbs are measured by presenting them to the main pathogenic antigens of interest (Figure 1 ) (Frenzel et al., 2016; Hess and Jewell, 2020) . It is noteworthy that the quality and size of such libraries are crucial in discovery of novel and more potent antibodies.

The best approach is to construct large phage libraries using the full repertoire of human antibodies to generate full-length antibodies (Pini and Bracci, 2000) . Hence, the complementarity determining region (CDR) located on antibodies that determine the binding of antigens demonstrate stronger affinity and ability to act against infectious antigens (Huang et al., 2012b) .

Marks and colleagues were the first to introduce a method to generate full-length antibodies using human antibody repertoire (Marks et al., 1991) . Mazor et al. established E-clonal approach, which enables isolation of full-length IgGs from phage displayed libraries (Mazor et al., 2008) . Phage display antibody libraries can be derived from both immunized (donors who have been exposed to the antigens) and non-immunized donors. The genome of non-immunized libraries can be exploited to generate a wide range of antibodies that will lead to the discovery of novel antibodies for novel antigens. On the other hand, antibodies from immunized libraries have a stronger affinity towards the antigen as they have gone through in vivo affinity maturation process (Richard et al., 2013) . MedImmune, Raxibacumab and human antibody AT005 are just a few examples of phage display contributed MAbs against respiratory syncytial virus (RSV) anthrax and cancer, respectively (Ran et al., 2005; Lagos et al., 2009; Mazumdar, 2009 ).

Using the strategy, different SARS-CoV-2 antigens like N, M and E proteins can be panned and targeted for different MAb libraries. After several affinity steps, the strongest MAbs can be screened against SARS-CoV-2. The rational idea behind this approach has been successfully used in finding MAbs for SARS-CoV (also known as SARS-CoV-1), the closest known viral relatives of SARS-CoV-2 (Wang et al., 2008) .

Taken all together, it is feasible to exploit the antibody repertoire of convalescent individuals to construct a large phage display library in which, after the screening procedures, several promising MAbs would be obtained. Furthermore, non-immunized phage display libraries can be used for developing novel antibodies for the upcoming SARS-CoV-2 variants which in turn may make phage display a beacon in the dark path of finding a perfect treatment for this burden on the health system. The proposed method is shown in Figure 1 .

Another application of phages and phage display in fighting against new pathogens is being used as inducer, booster or adjuvant of the immune system responses. In this concept, presenting the immunogenic antigen on a phage can lead to a more immediate and sophisticated immune response as discussed above (Zuercher et al., 2000; Ren et al., 2008) which is highly desired for vaccine development in general and SARS-CoV-2 in particular (Figure 1 ).

To date, over 300 projects were carried out on exploring new vaccines for the disease and a handful of those showed promising results which are being used worldwide (Forni and Mantovani, 2021) . Different platforms were exploited to develop these vaccines. DNA, mRNA and proteins of SARS-CoV-2 were used as antigens to stimulate the immune system. Phage display could be implemented to produce protein vaccines such as NVX-CoV2373 (Mahase, 2021) and Co-VLP (Shohag et al., 2021) with a high yield, specificity and potential to express various peptides. Viral vectors have been used in ChAdOx1, SputnikV and Ad26COVs1 and proved to be an efficient approach to induce immune response against SARS-CoV-2 (Forni and Mantovani, 2021) .

Similarly, bacteriophages may serve as new surrogates for the vaccine while playing an adjuvant role simultaneously.

Taken all together, phage display offers several exploitable advantages in developing new strategies to combat COVID-19 pandemic and its complications. Understanding the mechanisms J o u r n a l P r e -p r o o f of SARS-CoV-2 infection is of great importance, and phage display is an efficient means to study this virus's antigenic moiety and immunogenic properties.

Many studies reported the presence of SARS-CoV-2 in wastewater which raised a crucial concern that COVID-19 may enter different habitats and even drinking water resources through urban or agricultural runoff or wastewater. For instance, recent studies reported SARS-CoV-2 in rivers that are the final destination of untreated human waste (Lodder and de Roda Husman, 2020; Medema et al., 2020) . Although coronavirus load greatly decreases during primary and secondary wastewater treatment, there is still a potential risk that some viruses survive these stages and find their way into the treated wastewater (Mordecai and Hewson, 2020) . Considering the similarities between the ACE2 receptor in mammals, if such a thing occurs, the survived viruses may infect both aquatic and terrestrial mammals such as harbor seals (Luan et al., 2020a; Nabi and Khan, 2020) . In that sense the contaminated aquatic aerosols can become another carrier of viruses into terrestrial habitats. Therefore, in addition to regular monitoring of coronavirus at the inflow and outflow points of wastewater facilities, the development of effective treatment methods to remove viruses seems vital to prevent future viral epidemics.

SARS-CoV-2 is classified as a risk group (RG) 3 biological agent by European Commission (Hernández, 2020) , therefore not every research center would be able to work on this virus. The same applies to other viruses and pathogens of RG 3 and 4. This will greatly restrict the number of research centers for such studies. To tackle the issue, it is possible to use characteristically similar phages to such pathogens including coronaviruses. In other words, the alternative solution would focus on using non-pathogenic surrogates like bacteriophages. In addition to being safe, J o u r n a l P r e -p r o o f phages can be propagated easier, faster, and at a lower cost (because no high-tech facilities or equipment is required), the purification process of phage particles is not very complicated and the proliferation rate is higher and faster compared to animal viruses.

In that sense, among the discovered phages so far, the morphologically classified as non-tailed phages have the greatest resemblance to coronaviruses. Only a small percentage of the known phages (about 4%) are non-tailed (Khan Mirzaei et al., 2020) . Some members of this group have almost identical geometrical capsid shapes and produce protein appendages that are similar to coronaviruses' spike to some extent. Besides the morphological similarity, the genome (RNA or DNA, single-or double-strand) of a surrogate bacteriophage is also of importance as it can considerably affect the viral stability at different environmental stresses (Figure 2 ). Table 1 describes recent studies in which phage surrogates have replaced the pathogenic viruses. The titer of all the tested viruses was reduced rapidly and extensively by the ozone disinfection method. (Kowalski, morphological and genetic properties, the phages of Leviviridae family seems to be the best surrogates for coronavirus (Figure 2) but this should be first tested in vitro.

Studies on the effects of phages on immune cells are important for the applications of phages. Table 2 describes recent studies on the interactions between bacteriophages and immune cells.

Bacteriophages can play a protective role for eukaryotic cells against other viral infections by competing with adsorption or penetration of other viruses or even by inhibiting their propagation ( Table 2) . Bacteriophages are also capable of inducing antiviral immunity through activating specific pattern recognition receptors (PPRs) such as TLR3 and TLR9 or regulating the immune system responses by inhibiting reactive oxygen species (ROS) production or modulation of immune responses to maintaining a balance ( Table 2) . It has been shown than lung infection with respiratory viruses is associated with inflammation and cell death caused by excessive ROS production (Khomich et al., 2018) . The harmful action of ROS on the functions of both pulmonary cells and red blood cells (RBCs) can be seen as a major contributor to the hypoxic respiratory failure observed in the most severe cases of COVID-19 (Laforge et al., 2020) . Thus, most of the desirable effects of phages, like inhibiting the ROS, can play an important role in fighting against exciting or emerging COVID-19 infections. Another surface receptor for bacteriophages is the cell surfaces integrin which are important in phage uptake. It was shown that T4 phage inhibits the adsorption and replication of human adenovirus (HAdV) in human lung and kidney epithelial cells ( Table 2) . Attachment of T4 phage to integrin impairs HAdV attachment to the target cells through competitive binding to epithelial cell surface integrin via its KGD sequence (Przybylski et al., 2015) . In T4 phage, the integrin KGD motif (Lys-Gly-Asp) is present in the capsid protein (Dabrowska et al., 2007) . Since the KGD motif is conserved and expressed in many the exposed structural protein of many virus, the same potential inhibitory mechanism can be considered for any virus that has this motif, such as SARS-CoV in protein S (Luan et al., 2020b) . In other words, KGD+ phages can act as a protective layer against infection of eukaryotic cells by SARS-CoV-2. Phage encapsulated in electrostatically stabilized positively charged liposomes may enhance delivery to the cell surface.

It makes bacteriophage-encapsulated liposomes an appealing approach to treat antimicrobial J o u r n a l P r e -p r o o f infections.

Direct interaction of bacteriophages with immune cells can induce certain cytokines with important role in antimicrobial immunity (Górski et al., 2018) . For example, Pf phage and phage RNA genome can induce production of type Ⅰ interferon by triggering Toll-like receptor 3 (TLR3) (Sweere et al., 2019) . Additionally, Interferon γ (IFN-γ) production is stimulated by Lactobacillus, Escherichia and Bacteroides phages and phage DNA genome through triggering TLR9 (Gogokhia et al., 2019) . Both type Ⅰ interferon and IFN-γ are potent antiviral cytokines (Razaghi et al., 2016; Sallard et al., 2020) .

Moreover, intraperitoneal application of T4 purified phages inhibited ROS production by cells exposed to endotoxin (Miedzybrodzki et al., 2008) , which can reduce inflammation and inhibit cell death caused by ROX production in patients with a lung infection.

Bacteriophages can also regulate certain anti-inflammatory cytokines such as TNF production J o u r n a l P r e -p r o o f

Viral replication in pulmonary tissues could eventually results in a secondary bacterial infection by the opportunistic nosocomial pathogens (Tay et al., 2020) . In general, bacterial infections stimulate a stronger reaction by the innate immune system; hence, the invasion and growth of bacteria further stimulate the innate immune system, following which it secretes excess inflammatory material into the pulmonary alveoli. Add to this, additional bacterial load as a result of using artificial respiration which greatly facilitates entry and nesting of the invasive bacteria (Shi and Gewirtz, 2018) . This process is accelerated by the continuation of the viral attack on lung cells. Therefore, more and more dead cell debris is provided for bacteria to feed on. Not only recurrence of this cycle causes increased accumulation of inflammatory fluids in the lungs but it also drastically reduces gas exchange; eventually, respiration without artificial ventilation becomes impossible and, in severe cases, will cause a drastic decline in gas exchange, lowered blood oxygen, and sepsis which finally leads to the patient's death (Wojewodzic, 2020) . Inhibiting bacterial growth and their elimination in any way can decrease synthesis and secretion of lung fluid. If accompanied by reduced viral load, it can significantly improve the clinical manifestations of the disease and patient's condition.

Development of such secondary bacterial infections and the emergence of their clinical complications vary from case to case, but may take an average of 17 days (Wojewodzic, 2020) . It is important to mention that bacteria start colonization of the respiratory tract before causing the acute respiratory distress syndrome (Grijalva et al., 2014; Almand et al., 2017) . In that sense, theoretically, commencing the antibacterial therapy before the occurrence of the acute respiratory distress syndrome can significantly decrease the disease intensity.

Co-infections are frequently reported as common consequences in patients suffering from respiratory diseases such as cystic fibrosis, viral influenza, and even those infected by coronaviruses such as SARS and the Middle East respiratory syndrome (Schofield et al.) (Almand et al., 2017) . However, there is no precise and comprehensive information on the prevalence of co-infection in COVID-19 patients. The very few studies addressing co-infection demonstrated various prevalence rates for secondary infections in COVID-19 patients. At least 50% of dead casualties had progressive bacterial infections ( Table 3 ). The possibility of the disease becoming syndemic under health and social disparity conditions makes the matter worse (Mendenhall, 2020; Yadav et al., 2020) . Acinetobacter spp., and S. aureus confirming the role of these pathogens in respiratory infections (Chastre and Fagon, 2002; Bekaert et al., 2011) . Therefore, undoubtedly a considerable portion of COVID-19 mortality can be due to bacterial co-infections of the respiratory system (Hanuman Singh Dagur and Dhakar, 2020; Zhou et al., 2020) .

China (Chen et al., 2020b) Acinetobacter baumannii China Gram-positive and gram-negative organisms (organism NR) China

China Bacterial co-infection (organism NR) China Bacterial co-infection (organism NR) USA (Goyal et al., 2020) Bacterial co-infection (organism NR) USA (Arentz et al., 2020) Capnocytophagia 

China Mycoplasma pneumoniae USA (Richardson et al., 2020) Bacterial co-infection (organism NR) Italy (Zangrillo et al., 2020) Staphylococcus aureus UK (Hughes et al., 2020) Staphylococcus aureus China Mycoplasma pneumoniae Singapore Legionella pneumophila Japan (Dey and Ashbolt, 2020) Klebsiella pneumoniae Staphylococcus aureus - (Liew et al., 2020) Acinetobacter baumannii France In case of secondary infections, prescription of broad-spectrum antibiotics at high doses and sometimes multidrug therapies for patients can limit common bacterial infections. Reports indicate that more than 70% of the patients in the current COVID-19 pandemic receive various antibiotics J o u r n a l P r e -p r o o f (Hsu, 2020) . This further increases the risk of multidrug-resistant pathogens and the need to develop alternative strategies to fight bacterial infections in the post-COVID-19 era. Furthermore, as expected, antibiotics have a negligible effect because of the high frequency of resistant bacterial strains, formation of bacterial biofilm, and insufficient diffusion of antibiotics into the lungs (Strydom et al., 2019) . In other words, adequate delivery of the effective doses of antibiotics to the infection site seems impossible; also, bacteria exhibit a wide range of resistance.

Contrary to antibiotics, phage therapy is much less susceptible to the emergence of resistance.

One reason is the very high diversity of wild bacteriophages in nature (10 31 ). Another reason is their dynamic adaptation through mutation to new conditions such as emergence of resistance in the host. Moreover, phages can be easily engineered, which provide an inexhaustible source of antibacterial agents for researchers (Czaplewski et al., 2016) . Furthermore, although the rate of resistance to phages is much lower than resistance to antibiotics, only a single bacterial strain develops resistance to a phage as the phage's host range (the efficacy range) is extremely narrow and even specific (contrary to antibiotics that influence the entire bacterial population.

Phage therapy of human pulmonary infections caused by Staphylococci, Streptococci, Escherichia, Proteus, Klebsiella, Burkholderia and Pseudomonas dates back to more than 50 years ago (Abedon, 2015; Chang et al., 2018) . Over the past decades, inhaled phage therapy has been used against most of acute and chronic pulmonary bacterial infections (Semler et al., 2014; Pabary et al., 2016; Waters et al., 2017) . Intranasal (pulmonary) delivery of phages using bacteriophage suspension nebulizer or dry powder inhalers seems to be the best method of administration due to easy delivery of the phages by inhalation in the respiratory tree from its uppermost (the nose) to its lowermost parts (pulmonary alveoli) (Matinkhoo et al., 2011; Patey et al., 2018) .

Another important advantage of phage therapy is the phage activity influence on the immune

response. An in vivo study has shown that rapid bacterial lysis by phages in a pneumonia case stimulates a much weaker inflammatory response than antibiotic therapy (Dufour et al., 2019) .

This study clearly indicates that there will be no serious concerns over the outcomes of inflammatory responses related to extremely rapid bacterial lysis if phages are used. In contrast, these outcomes are much more common in terms of antibiotic therapy. However, emergence of phage-resistant strains is still remained a main concern for a successful phage therapy which is required more careful investigation.

The turning point in using phage therapy for treating pulmonary infections can be found in prevalent chronic infections in people with cystic fibrosis (CF) as a result of increased multiple drug resistance bacteria associated with lungs disease in recent years (Kortright et al., 2019) .

Successful phage therapy for the respiratory system is strictly time-dependent and early administration significantly reduces bacterial load (Morello et al., 2011; Semler et al., 2014; Waters et al., 2017) . (Table 4) , confirming the potential of phage therapy as a preventative or treatment strategy against secondary infections in COVID-19

pandemic. As mentioned above, in addition to studies on animal models, phage therapy of human pulmonary infections caused by Staphylococci, Streptococci, Escherichia, Proteus, Klebsiella and

Pseudomonas has been employed for many years (Abedon, 2015; Chang et al., 2018) . (Housby and Mann, 2009 ). These companies can play a critical and constructive role in speeding up the process involved in the development of lytic phages products.

Phages have a great promising potential in fighting COVID-19 pandemic. Previous research on phages reported their suitable and very effective performance in different fields of science. This article provided evidence that these biological entities can play a prominent role in improving secondary pulmonary infections by regulating immune responses or treating secondary or coinfections. Bacteriophages offer many potential applications in epitope mapping, antigen display, and surrogate agents in clinical, epidemiological or environmental studies. High abundance, inexpensive production on a large scale, compatibility with the environment, lack of known side effects as of now, morphological and genetic similarity to coronavirus, and ease of manipulation are some of the advantages of using bacteriophages in SARS-CoV-2 related research. Phage therapy may also be considered an effective solution for respiratory infections considering the post-COVID-19 era and the potential emergence of bacterial superbugs. Moreover, the need to detect coronavirus in public places and the limitations of using coronavirus in research confirm the need to have viral models. Furthermore, phage display is a highly effective platform for developing precise and easily accessible detection tools, novel vaccines and antibodies. Recent evidence demonstrated desirable regulating effects of phages on the host immune response, such as reducing inflammatory responses, which can have a special role in improving the general condition of corona patients. Considering the high prevalence of secondary infections, the most J o u r n a l P r e -p r o o f significant advantage of phages is their capacity to cope with bacterial infections because they can increase the survival rate of patients and prevent the further emergence of antibiotic resistance.

This study was supported by funds from the National Natural Science Foundation of China (NSFC No. 31950410562 and 31602078) and Natural Science Foundation Jiangsu Province (BK20180054). Since parts of the writing took place at IPS/CAS, we also acknowledge the Shanghai Municipal Science and Technology Major Project (#2019SHZDZX02).

The authors declare that they have no conflict of interest. 

Phage therapy of pulmonary infections

The use of bacteriophages of the family Cystoviridae as surrogates for H5N1 highly pathogenic avian influenza viruses in persistence and inactivation studies

Phage display as a promising approach for vaccine development

Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells

Virus-Bacteria Interactions: An Emerging Topic in Human Infection

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Bats and Coronaviruses

Morphologic and genomic characterization of a broad host range Salmonella enterica serovar Pullorum lytic phage vB_SPuM_SP116

The complete genome of lytic Salmonella phage vB_SenM-PA13076 and therapeutic potency in the treatment of lethal Salmonella Enteritidis infections in mice

Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis

The Effects of T4 and A3/R Bacteriophages on Differentiation of Human Myeloid Dendritic Cells

Viral and Bacterial Interactions in the Upper Respiratory Tract

Emerging viruses in marine mammals

Acute necrotizing enteritis associated with suspected coronavirus infection in three harbor seals (Phoca vitulina)

Effectiveness of Ultraviolet-C Light and a High-Level Disinfection Cabinet for Decontamination of N95 Respirators

Expansion of known ssRNA phage genomes: From tens to over a thousand

Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice

Isolation and characterization of a "phiKMV-like" bacteriophage and its therapeutic effect on mink hemorrhagic pneumonia

Effects of air temperature and relative humidity on coronavirus survival on surfaces

Phage therapy for respiratory infections

Ventilator-associated pneumonia

The KGD Motif of Epstein-Barr Virus gH/gL Is Bifunctional

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 43

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice

Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development

A structural model for the Coronavirus Nucleocapsid

Alternatives to antibioticsa pipeline portfolio review

Hoc protein regulates the biological effects of T4 phage in mammals

Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses

Legionella Infection during and after the COVID-19 Pandemic

Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review

Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages

Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of the Inflammatory Response Compared to Antibiotic Treatment in Mice

COVID-19 and mycoplasma pneumoniae coinfection

Potential T-cell and B-cell Epitopes of 2019-nCoV. bioRxiv

Comparative inactivation of poliovirus type 3 and MS2 coliphage in demand-free phosphate buffer by using ozone

A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera

COVID-19 vaccines: where we stand and challenges ahead

Phage display-derived human antibodies in clinical development and therapy

A (Bio)anthropological View of the COVID-19 Era Midstream: Beyond the Infection

Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis

Bacterial infections and patterns of antibiotic use in patients with COVID-19

Perspectives of Phage-Eukaryotic Cell Interactions to Control Epstein-Barr Virus Infections

Clinical Characteristics of Covid-19 in

SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19

The role of influenza and parainfluenza infections in nasopharyngeal pneumococcal acquisition among young children

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Rapid repurposing of drugs for COVID-19

Genome Organization of Covid-19 and Emerging Severe Acute Respiratory Syndrome Covid-19 Outbreak: A Pandemic

Predicting In Vivo Efficacy of Therapeutic Bacteriophages Used To Treat Pulmonary Infections

SARS-CoV-2 risk misclassification explains poor COVID-19 management

Phage display as a tool for vaccine and immunotherapy development

Phage therapy

Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report

How covid-19 is accelerating the threat of antimicrobial resistance

Identification of a Mimotope Peptide Bound to the SARS-CoV Spike Protein Specific Monoclonal Antibody 2C5 with Phage-displayed Peptide Library

Clinical features of patients infected with

Development of Anti-Infectives Using Phage Display: Biological Agents against Bacteria, Viruses, and Parasites

Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Inactivation of MS2 Bacteriophage and Adenovirus with Silver and Copper in Solution and Embedded in Ceramic Water Filters

Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia

Challenges of Studying the Human Virome -Relevant Emerging Technologies

Redox Biology of Respiratory Viral Infections

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets

Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria

Ultraviolet Germicidal Irradiation Handbook

Severity of coronavirus respiratory tract infections in adults admitted to acute care in

Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens

Tissue damage from neutrophil-induced oxidative stress in COVID-19

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected childrenCHILDREN

Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia

Clinics in Diagnostic Imaging: COVID-19 atypical pneumonia

Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

SARS-CoV-2 in wastewater: potential health risk, but also data source

SARS-CoV-2 spike protein favors ACE2 from Bovidae and Cricetidae

A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Inactivation of E. coli, B. subtilis spores, and MS2, T4, and T7 phage using UV/H2O2 advanced oxidation

MXene-laden bacteriophage: A new antibacterial candidate to control bacterial contamination in water

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

Compounds with Therapeutic Potential against Novel Respiratory

Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections

E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display

Presence of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early Stage of the Epidemic in The Netherlands

The COVID-19 syndemic is not global: context matters

A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes

Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes

Coronaviruses in the Sea

Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and Prevention

Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers

Detection of a respiratory coronavirus from tissues archived during a pneumonia epizootic in free-ranging Pacific harbor seals Phoca vitulina richardsii

Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung

Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections

Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with a chimeric antigen

Phage display of antibody fragments

T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro

Inhibitory Effects of Bacteriophage Preparations on Adenoviral Replication

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice

Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation

Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice

In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen

An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors

Type 1 interferons as a potential treatment against COVID-19

Natural bacteriophages T4 and M13 downregulates Hsp90 gene expression in human prostate cancer cells (PC-3) representing a potential nanoparticle against cancer

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera

Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein

Chapter 20 -Coronaviruses in Aquatic Organisms

Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy

Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections

Bio-control of O157:H7, and colistinresistant MCR-1-positive Escherichia coli using a new designed broad host range phage cocktail. LWT, 154

Biodiversity of New Lytic Bacteriophages Infecting Shigella spp. in Freshwater Environment

A New Phage Cocktail Against Multidrug, ESBL-Producer Isolates of Shigella sonnei and Shigella flexneri with Highly Efficient Bacteriolytic Activity

Effective control of Shigella contamination in different foods using a novel six-phage cocktail

An in-vitro study on a novel six-phage cocktail against multi-drug resistant-ESBL Shigella in aquatic environment

Together Forever: Bacterial-Viral Interactions in Infection and Immunity

Reduction of Norwalk virus, poliovirus 1, and bacteriophage MS2 by ozone disinfection of water

COVID-19 Crisis: How Can Plant Biotechnology Help? Plants 10

Systematic Review and Meta-Analysis of the Persistence and Disinfection of Human Coronaviruses and Their Viral Surrogates in Water and Wastewater

Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic

Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection

Ability of human polymorhonuclear blood cells to produce interferon after induction with phage double-stranded RNA

Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice

The trinity of COVID-19: immunity, inflammation and intervention

Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis

Diagnosing COVID-19: The Disease and Tools for Detection

Pro-and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

The respiratory virome and exacerbations in patients with chronic obstructive pulmonary disease

Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection

A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro

Clinical Features of 69 Cases With Coronavirus Disease

Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa

Bacteriophage Therapy of Bacterial Infections: An Update of our Institute's Experience," in Inflammation

Cell-free expression of RNA encoded genes using MS2 replicase

Persistence of Bacteriophage Phi 6 on Porous and Nonporous Surfaces and the Potential for Its Use as an Ebola Virus or Coronavirus Surrogate

Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19)

Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in Gammacoronavirus

Evaluating the Environmental Persistence and Inactivation of MS2 Bacteriophage and the Presumed Ebola Virus Surrogate Phi6 Using Low Concentration Hydrogen Peroxide Vapor

Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19

Influence of algal organic matter of Microcystis aeruginosa on ferrate decay and MS2 bacteriophage inactivation

Adsorption of bacteriophage MS2 to colloids: Kinetics and particle interactions

A Syndemic Perspective on the Management of Non-communicable Diseases Amid the COVID-19 Pandemic in Low-and Middle-Income Countries

Therapeutic effect of the YH6 phage in a murine hemorrhagic pneumonia model

Isolation, Characterization and Genomic Analysis of a Novel Bacteriophage VB_EcoS-Golestan Infecting Multidrug-Resistant Escherichia coli Isolated from

Reactivity of Enveloped Virus Genome, Proteins, and Lipids with Free Chlorine and UV254

Survivability, Partitioning, and Recovery of Enveloped Viruses in Untreated Municipal Wastewater

Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Staphylococcus aureus Bacteriophage Suppresses LPS-Induced Inflammation in MAC-T Bovine Mammary Epithelial Cells

Phage JS02, a putative temperate phage, a novel biofilm-degrading agent for Staphylococcus aureus

Antiviral effect of a bacteriophage on murine norovirus replication via modulation of the innate immune response

Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma

B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Oral anti-IgE immunization with epitope-displaying phage

The authors would like to thank all colleagues who made this research successful.J o u r n a l P r e -p r o o f